Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $38M (up 16.5% year over year) with net income of −$17M.
Q3 2025 key financials · XBRL
- Revenue
- $38M
- +16.5% YoY · +2.7% QoQ
- Net income
- −$17M
- −260.9% YoY · −634.8% QoQ
- Operating margin
- -10.7%
- Gross margin
- 68.8%
- EPS (diluted)
- −$0.11
- −266.7% YoY · −1000.0% QoQ
Source: XBRL data from the HERON THERAPEUTICS, INC. /DE/ (HRTX) Q3 2025 10-Q on SEC EDGAR. USD.
HERON THERAPEUTICS, INC. /DE/ Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $38.2M, up 16.5% YoY from $32.8M
- Gross margin 68.8% vs 71.2% YoY; operating margin (9.7%) vs (13.6%)
- Best segment Acute Care sales $12.3M, up 67.2%; Oncology sales $25.9M, up 1.7%
- Cash, equivalents and short-term investments $55.5M; nine-month operating cash use $18.4M vs $10.7M
- Outlook: SUSTOL commercialization wind-down over next 12 months; oncology competition expected to continue foreseeable future
Risk Factors
- Newly emphasized regulatory risk: FDA, HHS, CDC, and NIH layoffs and reorganizations could delay drug reviews, approvals, and inspections
- Most materially updated trade risk: 100% tariff on branded or patented pharmaceutical imports effective October 1, 2025, currently delayed
- Compliance risk: Supreme Court decisions and executive orders may subject FDA regulatory actions to presidential supervision and control
- Operational risk: tariff-related supplier or manufacturing-partner changes could disrupt production and derail commercialization plans
- Market risk: retaliatory tariffs could disrupt global markets, escalate geopolitical tensions, and increase sourcing costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HERON THERAPEUTICS, INC. /DE/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.